PatchG
2021-08-02
Too early but Pharma always ready for legal
Pfizer, Moderna Hike Prices Of Vaccine Shots Supplied To EU: Report
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":805809834,"tweetId":"805809834","gmtCreate":1627867966728,"gmtModify":1633755801660,"author":{"id":4088070664933270,"idStr":"4088070664933270","authorId":4088070664933270,"authorIdStr":"4088070664933270","name":"PatchG","avatar":"https://static.tigerbbs.com/bf19f71e0afadca38d3167c641e1c912","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":7,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Too early but Pharma always ready for legal </p></body></html>","htmlText":"<html><head></head><body><p>Too early but Pharma always ready for legal </p></body></html>","text":"Too early but Pharma always ready for legal","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/805809834","repostId":1162208746,"repostType":4,"repost":{"id":"1162208746","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1627865676,"share":"https://www.laohu8.com/m/news/1162208746?lang=&edition=full","pubTime":"2021-08-02 08:54","market":"us","language":"en","title":"Pfizer, Moderna Hike Prices Of Vaccine Shots Supplied To EU: Report","url":"https://stock-news.laohu8.com/highlight/detail?id=1162208746","media":"Benzinga","summary":"Pfizer, Inc. and Moderna, Inc., which have already minted billions of dollars from their respective ","content":"<p><b>Pfizer, Inc.</b> and <b>Moderna, Inc.</b>, which have already minted billions of dollars from their respective COVID-19 vaccines, remain poised to earn more.</p>\n<p><b>What Happened:</b>Pfizer and Moderna have both renegotiated their vaccine supply contract with the European Union, the FT reported Sunday.</p>\n<p>The contract terms for the supply of up to 2.1 billion vaccine shots were revised after the release of the Phase 3 data, the report said. Late-stage study of the mRNA vaccine Pfizer is co-developing with <b>BioNTech SE</b> showed vaccine efficacy of 95%, while a similar class of vaccine developed by Moderna boasted vaccine efficacy of 94.1%.</p>\n<p>In comparison,<b>Johnson & Johnson's</b> single-dose shot, which is authorized for use in the U.S., showed overall efficacy of 72%.</p>\n<p><b>AstraZeneca plc's</b> COVID-19 vaccine made from inactivated adenovirus was found to be 76% effective at reducing the risk of symptomatic disease, 15 days or more after receiving two doses.</p>\n<p>Additionally, authorized vaccines from J&J and AstraZeneca have been linked to stray incidences of severe blood clots.</p>\n<p>Pfizer and Moderna have managed to expand the age range of their vaccines to include adolescents and they are also running trials on pediatric population. The companies are working on booster doses that may prove effective against variants and also on variant-specific vaccines.</p>\n<p>The FT report states that Pfizer has increased the price of its vaccine from the originally contracted amount of 15.50 euros ($18.39) to 19.50 euros per dose. The Moderna shot price has been increased from $22.60 to $25.50.</p>\n<p><b>Why It's Important:</b>Pfizer and Moderna are able to dictate terms, as the world still grapples with the novel coronavirus, especially with the emergence of variants.</p>\n<p>The EU is also under pressure to procure more supplies, as countries within the block have decried unfair vaccine distribution among member nations, the FT reported.</p>\n<p>Pfizer's second-quarter results released last week showed that the pharma giant clocked in COVID-19 vaccine revenues of roughly $8 billion in the second quarter. The company also raised its vaccine revenue forecast for 2021 from $26 billion to $33.5 billion.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer, Moderna Hike Prices Of Vaccine Shots Supplied To EU: Report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer, Moderna Hike Prices Of Vaccine Shots Supplied To EU: Report\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-02 08:54</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Pfizer, Inc.</b> and <b>Moderna, Inc.</b>, which have already minted billions of dollars from their respective COVID-19 vaccines, remain poised to earn more.</p>\n<p><b>What Happened:</b>Pfizer and Moderna have both renegotiated their vaccine supply contract with the European Union, the FT reported Sunday.</p>\n<p>The contract terms for the supply of up to 2.1 billion vaccine shots were revised after the release of the Phase 3 data, the report said. Late-stage study of the mRNA vaccine Pfizer is co-developing with <b>BioNTech SE</b> showed vaccine efficacy of 95%, while a similar class of vaccine developed by Moderna boasted vaccine efficacy of 94.1%.</p>\n<p>In comparison,<b>Johnson & Johnson's</b> single-dose shot, which is authorized for use in the U.S., showed overall efficacy of 72%.</p>\n<p><b>AstraZeneca plc's</b> COVID-19 vaccine made from inactivated adenovirus was found to be 76% effective at reducing the risk of symptomatic disease, 15 days or more after receiving two doses.</p>\n<p>Additionally, authorized vaccines from J&J and AstraZeneca have been linked to stray incidences of severe blood clots.</p>\n<p>Pfizer and Moderna have managed to expand the age range of their vaccines to include adolescents and they are also running trials on pediatric population. The companies are working on booster doses that may prove effective against variants and also on variant-specific vaccines.</p>\n<p>The FT report states that Pfizer has increased the price of its vaccine from the originally contracted amount of 15.50 euros ($18.39) to 19.50 euros per dose. The Moderna shot price has been increased from $22.60 to $25.50.</p>\n<p><b>Why It's Important:</b>Pfizer and Moderna are able to dictate terms, as the world still grapples with the novel coronavirus, especially with the emergence of variants.</p>\n<p>The EU is also under pressure to procure more supplies, as countries within the block have decried unfair vaccine distribution among member nations, the FT reported.</p>\n<p>Pfizer's second-quarter results released last week showed that the pharma giant clocked in COVID-19 vaccine revenues of roughly $8 billion in the second quarter. The company also raised its vaccine revenue forecast for 2021 from $26 billion to $33.5 billion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1162208746","content_text":"Pfizer, Inc. and Moderna, Inc., which have already minted billions of dollars from their respective COVID-19 vaccines, remain poised to earn more.\nWhat Happened:Pfizer and Moderna have both renegotiated their vaccine supply contract with the European Union, the FT reported Sunday.\nThe contract terms for the supply of up to 2.1 billion vaccine shots were revised after the release of the Phase 3 data, the report said. Late-stage study of the mRNA vaccine Pfizer is co-developing with BioNTech SE showed vaccine efficacy of 95%, while a similar class of vaccine developed by Moderna boasted vaccine efficacy of 94.1%.\nIn comparison,Johnson & Johnson's single-dose shot, which is authorized for use in the U.S., showed overall efficacy of 72%.\nAstraZeneca plc's COVID-19 vaccine made from inactivated adenovirus was found to be 76% effective at reducing the risk of symptomatic disease, 15 days or more after receiving two doses.\nAdditionally, authorized vaccines from J&J and AstraZeneca have been linked to stray incidences of severe blood clots.\nPfizer and Moderna have managed to expand the age range of their vaccines to include adolescents and they are also running trials on pediatric population. The companies are working on booster doses that may prove effective against variants and also on variant-specific vaccines.\nThe FT report states that Pfizer has increased the price of its vaccine from the originally contracted amount of 15.50 euros ($18.39) to 19.50 euros per dose. The Moderna shot price has been increased from $22.60 to $25.50.\nWhy It's Important:Pfizer and Moderna are able to dictate terms, as the world still grapples with the novel coronavirus, especially with the emergence of variants.\nThe EU is also under pressure to procure more supplies, as countries within the block have decried unfair vaccine distribution among member nations, the FT reported.\nPfizer's second-quarter results released last week showed that the pharma giant clocked in COVID-19 vaccine revenues of roughly $8 billion in the second quarter. The company also raised its vaccine revenue forecast for 2021 from $26 billion to $33.5 billion.","news_type":1},"isVote":1,"tweetType":1,"viewCount":59,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":36,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/805809834"}
精彩评论